Top Banner
Ronald E. LaPorte
61

Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Dec 23, 2015

Download

Documents

Caitlin Ellis
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Ronald E. LaPorte

Page 2: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Janice Dorman, Ph.D.DirectorMolecular Epidemiology

Ronald LaPorte, Ph.D.DirectorDisease Monitoring and Telecommunications

WHO CollaboratingCenter

GSPH

Page 3: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

The Importance of Type 1Registries

Page 4: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.
Page 5: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Diabetes Epidemiology Team in Pittsburgh

• Allan Drash, M.D.• Dorothy Becker, M.D.• Janice Dorman, Ph.D.• Lewis Kuller, M.D., Dr.PH• Ronald LaPorte, Ph.D.• Trevor Orchard, M.D.• Thomas Songer, Ph.D.• Massimo Trucco, M.D.

Page 6: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Type I Diabetes the Epidemiologist’sDream Disease

Easy to DiagnosisFrequent but not too frequentSevere but not too severeInsulinDynamic Epidemiology

Page 7: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Excess Mortality

0

1

2

3

4

5

6

7

8

9

Type I Type II

Page 8: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Chronic Diseases in Children

0

2

4

6

8

10

12

14

16

Type I CA CF MS JRA MD

Page 9: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

• Identical Twins = 35%• HLA Identical = 18%• non asp 57 = 2%

Page 10: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.
Page 11: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

PreventionPrevention

19701970

ICAICA

HLA BHLA B

Childhood diabetes

Page 12: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

PreventionPrevention

Insulin AntibodiesInsulin Antibodies

HLA DRHLA DR

19801980 Type I diabetes

Page 13: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

PreventionPrevention

HLA DQHLA DQ

19901990

CyclosporinCyclosporin

Insulin DependentDiabetes

Page 14: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

PreventionPrevention

20202020

ICA 7873ICA 7873

T cell receptor GeneT cell receptor Gene

Growth Hormone TherapyGrowth Hormone Therapy

Name--Unknown

Page 15: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

The Search for the Magic BulletThe Search for the Magic Bulletto Prevent Type I Diabetesto Prevent Type I Diabetes

Page 16: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

PreventionPreventionof Type Iof Type I

Toxic!!!Toxic!!!

Page 17: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Let observations with extensive viewSurvey mankind from China to Peru

S. Johnson, 1749

Page 18: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

The Environmental

in Preventing Diabetes

Challenge

Page 19: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Environmental Etiology of Type I diabetes

• Environmental agents causes disease in animals

• Geographic Variation• Temporal Variation• Migrants take on risk of new

environment• Environmental Factors Found to

Cause Disease in the Population

Page 20: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Prevention:

Reducing the incidence of disease

Last, Dictionary of Epidemiology

Page 21: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Environmental Etiology of Type I diabetes

• Environmental agents causes disease in animals

• Geographic Variation• Temporal Variation• Migrants take on risk of new

environment• Environmental Factors Found to

Cause Disease in the Population

Page 22: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Type I diabetes Incidence

FIN

SWD

NOR

UK

PLD

JPN

PRC

0 5 10 15 20 25 30 35

FIN

SWD

NOR

UK

PLD

JPN

PRC

Page 23: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Environmental Etiology of Type I diabetes

• Environmental agents causes disease in animals

• Geographic Variation• Temporal Variation• Migrants take on risk of new

environment• Environmental Factors Found to

Cause Disease in the Population

Page 24: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Allegheny County, PA

0

5

10

15

20

25

65-69 70-74 75-79 80-84 85-89

White Males

NW Males

Page 25: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

US Virgin Islands

0

5

10

15

20

25

30

1979 1981 1983 1985 1987

Page 26: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Environmental Etiology of IDDM

• Environmental agents causes disease in animals

• Geographic Variation• Temporal Variation• Migrants take on risk of new

environment• Environmental Factors Found to

Cause Disease in the Population

Page 27: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Migration Effects

02468

10121416

Chinese Jewish French

Source Migrant

Page 28: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.
Page 29: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Asian Migration to UK

0

2

4

6

8

10

12

14

16

18

1972 1974 1976 1978 1980 1982 1984

English

Asian-English

Page 30: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

A Public Health Approach Towards Prevention of IDDM

Page 31: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Green mountains range beyond the northern wall

White water rushes round the eastern town

right here is where, alone and restless, he

begins a journey of a thousand miles.

While travelers’ intents are fleeting clouds,

A friend’s affection is a setting sun.

He waves good-bye, and as he goes from here,

His dappled horse lets out a lonely neigh.

Page 32: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Where will the agent be found?

0

5

10

15

20

25

30

1979 1981 1983 1985 1987

Page 33: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

The Importance of IDDM Registries

Page 34: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Establishment of Population Based Registries for 1990-99

• Diagnosed as IDDM• On Insulin at Hospital discharge• Diagnosed between 1/1/90 and

31/12/99• Age at onset 0-14• Member of a defined community• Secondary Source of Case

Identification

Page 35: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

WHO DiaMond ProjectWHO DiaMond Project

Page 36: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

WHO DiaMond ProjectWHO Multinational Project for Childhood DiabetesWHO Diabetes Mondiale

• 155 Centers• 70 Countries• 7.2% of the World’s

Children

Page 37: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

16000 New Cases16000 New Cases

At China rate = 56 CasesAt China rate = 56 Cases

Page 38: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.
Page 39: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

The south sweet,the north saltthe east pungentand the west sour

Page 40: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Chinese Academy ofPreventive Medicine

Page 41: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

56 different Nationalities

Page 42: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

WHO DiaMond ProjectWHO DiaMond Project

Yang ZeBeijing Hospital

Page 43: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

To evaluate the incidence of IDDM in China

• Set up a collaborative registry network;

• Based on DiaMond standard protocol

• 22 Type 1 registry centers in China.

WHO DiaMond Project WHO DiaMond Project

Page 44: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

A gracefully executed work

Page 45: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Jan Alice Lew

Yang Ze

Page 46: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Logistics of Registration

• Research Workers 233• Registry Sources 6• Hospitals 753• Schools 12557• Population covered

83,575,028• Population <15 yrs

20,659,472

Page 47: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Percent Ascertainment by Center

0

10

20

30

40

50

60

70

80

90

100

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Overall = 94.5%

Page 48: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Global Incidence of IDDM

0 5 10 15 20 25 30 35

FIN

CAN

SWD

SCOT

NOR

US

UK

DEN

PLD

Cuba

JPN

MEX

PRC

Page 49: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

0 0.5 1 1.5 2

Geographic Variation Within China

Page 50: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Age at Onset

0

0.5

1

1.5

2

2.5

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Females

Males

Page 51: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

North South variation

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

North South

Page 52: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Ethnic Group

0 0.5 1 1.5 2 2.5

Zhuang

Han

Man

Korean

Hui

Ulguir

Mongol

5-Fold

Page 53: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

If one does not store up vital forces in the winter, he will be sure to suffer from an epidemic in the spring

Page 54: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Gulin

0

0.2

0.4

0.6

0.8

1

1.2

1.4

89 90 91 92 93 94

Page 55: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Tracking Down the Etiology of IDDM

Molecular Epidemiology Studies (WHO DiaMond, Jan Dorman)

Ecologic RelationshipsOutbreak InvestigationsCase-crossover design

Monitor Incidence

Page 56: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Chinese Migrants

0 0.5 1 1.5 2 2.5

PRC

Taiwan

Singapore

Hong K ong

4-fold

Page 57: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Public Health Prevention

• Monitor Incidence Rapidly• Identify Epidemics• Outbreak Investigations• Reduction of factor

Page 58: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Prevention

Identification of Identification of Precipitating FactorsPrecipitating Factors

Monitoring IDDM Monitoring IDDM IncidenceIncidence

Reduction of Reduction of Precipitating FactorsPrecipitating Factors

Page 59: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Prevention

Diabetes Epidemiology

InformationSuperhighway

Page 60: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Talking Points

• We know more about the incidence of Type 1 diabetes than any chronic disease. Why cannot we find the environmental factor?

• Type 1 diabetes is increase in almost all countries, what might be driving this?

• The Pattern of Type 1 diabetes is virtually the same as rheumatic fever, the early part of the center. Why does this give us hope to find its cause?

Page 61: Ronald E. LaPorte Janice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and Telecommunications WHO Collaborating.

Review Questions (Developed by the Supercourse team)

• Why is Type 1 diabetes considered to be a “dream disease” for epidemiologists•For 30 years we have been told that the cure to type 1 diabetes is around the corner, while Type 1 diabetes has never been prevented. Why?•Epidemiology of Type 1 diabetes typically focuses on incidence, and type 2 on prevalence, Why?